A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension

Condition:   Pulmonary Arterial Hypertension Interventions:   Drug: Treprostinil Palmitil;   Drug: Placebo Sponsor:   Insmed Incorporated Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

Journal of Human Hypertension, Published online: 27 January 2022; doi:10.1038/s41371-021-00651-zMalignant hypertension and atypical hemolytic uremic syndrome: a possible continuum between two entities?
Source: Journal of Human Hypertension - Category: Cardiology Authors: Source Type: research
Journal of Human Hypertension, Published online: 27 January 2022; doi:10.1038/s41371-021-00652-yFocus on today’s evidence while keeping an eye on the future: lessons derived from hypertension in women
Source: Journal of Human Hypertension - Category: Cardiology Authors: Source Type: research
Conditions:   Pulmonary Arterial Hypertension;   Erectile Dysfunction Intervention:   Drug: TPN171H single dose Sponsors:   Vigonvita Life Sciences;   Shanghai Institute of Materia Medica, Chinese Academy of Sciences Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Hypertension Intervention:   Behavioral: Adherence Sponsor:   Pham Ngoc Thach University of Medicine Active, not recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Patients With Pulmonary Hypertension Intervention:   Other: echocardiography Sponsor:   Sohag University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conclusions (i.e., comparable) are based on an overlap of pairwise 95 percent credible intervals.1c. PASI 90 is defined as at least 90 percent improvement from baseline in the PASI score. The PASI score grades the amount of surface area on each body region that is covered by PsO plaques and the severity of plaques for their redness, thickness, and scaliness.13 PASI 90 was not a controlled endpoint in DISCOVER-1 or -2.8,9d. TREMFYA q4w dosing is not currently FDA-approved.2e. The PsA-modified vdH-S score combines erosion and joint space narrowing scores derived from radiographs of joints in body regions impacted by PsA.14 T...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
Conclusions: EVVP in normal controls is a congenital phenomenon that exerts no impact on ICP. However, the presence of EVVP reduces ICP and alleviates IH-related papilledema and tinnitus in BTSS patients.Cerebrovasc Dis
Source: Cerebrovascular Diseases - Category: Neurology Source Type: research
Conclusions: The mortality rate was higher in older patients with comorbidities s uch as hypertension and CVD. Early recognition of high-risk patients may help to improve care and reduce mortality.
Source: Medical Principles and Practice - Category: Internal Medicine Source Type: research
CONCLUSIONS: The plasma proteome informs prognosis beyond established factors in PAH and may provide a more sensitive measure of therapeutic response.PMID:35081018 | DOI:10.1164/rccm.202105-1118OC
Source: American Journal of Respiratory and Critical Care Medicine - Category: Respiratory Medicine Authors: Source Type: research
CONCLUSION: Epigenetic regulation of the VWF promotor contributes to the creation of a local environment that favors in situ thrombosis in the pulmonary arteries. It reveals a direct molecular link between inflammatory pathways and platelet adhesion in the pulmonary vascular wall, emphasizing a possible role of in situ thrombosis in the development or progression of CTEPH.PMID:35081007 | DOI:10.1164/rccm.202109-2075OC
Source: American Journal of Respiratory and Critical Care Medicine - Category: Respiratory Medicine Authors: Source Type: research
More News: Hypertension | Research | Study